Information de reference pour ce titreAccession Number: | 01445483-201009150-00017.
|
Author: | Ibarretxe-Bilbao, Naroa PhD; Junque, Carme PhD; Marti, Maria-Jose MD, PhD; Valldeoriola, Francesc MD, PhD; Vendrell, Pere PhD; Bargallo, Nuria MD, PhD; Zarei, Mojtaba MD MRCP; Tolosa, Eduardo MD, PhD
|
Institution: | (1)Centro de Investigacion en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic de Barcelona, Spain (2)Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Spain (3)Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (4)Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociencies (ICN), Hospital Clinic de Barcelona, Spain (5)Centre de Diagnostic per la Imatge Hospital Clinic de Barcelona (CDIC), Hospital Clinic de Barcelona, Spain (6)Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), University of Oxford, United Kingdom
|
Title: | |
Source: | Movement Disorders. 25(12):1888-1894, September 15, 2010.
|
Abstract: | colon; Olfactory dysfunction is known to occur before the appearance of the classical motor signs in Parkinson's disease (PD) and diffusion tensor imaging (DTI) studies in PD have reported fractional anisotropy (FA) reductions in the early disease stages. We aimed to investigate the relationship between olfactory dysfunction and white matter (WM) FA of central olfactory areas in early PD. Twenty-four patients at Hoehn and Yahr stages I and II and 24 healthy controls matched by age, gender and years of education participated in this study. DTI was acquired at a 3 Tesla scanner and odor identification was assessed using the University of Pennsylvania Smell Identification Test (UPSIT). We performed FA voxelwise group comparisons in the central olfactory structures using tract-based spatial statistics (TBSS) and correlation analyses between FA values in these central olfactory areas and UPSIT scores. Patients with severe microsmia (UPSIT between 19 and 25) and anosmia (UPSIT lower or equal to 18) had lower FA values than PD patients with mild/moderate or no olfactory dysfunction (UPSIT between 26 and 40) and healthy controls in the WM adjacent to gyrus rectus. In addition, patients with anosmia had reduced FA in the WM surrounding primary olfactory areas in comparison with healthy controls. FA values in the WM adjacent to primary olfactory cortex and right gyrus rectus correlated with UPSIT scores in the PD group. This study demonstrates, for the first time, that microstructural WM reductions are present in the central olfactory system of early stage PD patients and that these reductions are associated with reduced ability to smell. (C) 2010 Movement Disorder Society
(C) 2010 John Wiley & Sons, Ltd
|
Author Keywords: | MRI; olfaction; DTI; UPSIT; TBSS.
|
References: | 1. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-1244.
2. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:138-142.
3. Stern MB, Doty RL, Dotti M, et al. Olfactory function in Parkinson's disease subtypes. Neurology 1994;44:266-268.
4. Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 1998;55:84-90.
5. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001;16:41-46.
6. Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50:34-41.
7. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-181.
8. Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009;72(7 Suppl):S12-S20.
9. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008;63:167-173.
10. Price JL. Olfaction. In: Paxinos G, Mai JK, editors. The human nervous system, second ed. Amsterdam, Elsevier; 2004.
11. Gottfried JA, Zald DH. On the scent of human olfactory orbitofrontal cortex: meta-analysis and comparison to non-human primates. Brain Res Brain Res Rev 2005;50:287-304.
12. West SE, Doty RL. Influence of epilepsy and temporal lobe resection on olfactory function. Epilepsia 1995;36:531-542.
13. Moore JK, Linthicum FH. Auditory system. In: Paxinos G, Mai JK, editors. The human nervous system, second ed. Elsevier; 2004.
14. Siderowf A, Newberg A, Chou KL, et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 2005;64:1716-1720.
15. Westermann B, Wattendorf E, Schwerdtfeger U, et al. Functional imaging of the cerebral olfactory system in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2008;79:19-24.
16. Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 2006;129 (Part 2):538-542.
17. Zhang K, Yu C, Zhang Y, et al. Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease. Eur J Radiol (in press).
18. Moseley ME, Cohen Y, Kucharczyk J, et al. Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. Radiology 1990;176:439-445.
19. Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001;13:534-546.
20. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry 2004;75:481-484.
21. Karagulle Kendi AT, Lehericy S, Luciana M, Ugurbil K, Tuite P. Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol 2008;29:501-505.
22. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-1384.
23. Zarei M, Damoiseaux JS, Morgese C, et al. Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. Stroke 2009;40:773-779.
24. Damoiseaux JS, Smith SM, Witter MP, et al. White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp 2009;30:1051-1059.
25. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39:165-172.
26. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314-2324.
27. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984;32:489-502.
28. Doty RL. The Smell Identification Test(TM) Administration manual, Third ed.. Haddon Hts: Sensonics; 1995.
29. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487-1505.
30. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(Suppl 1):S208-S219.
31. Mori S, Oishi K, Jiang H, et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage 2008;40:570-582.
32. Doty RL, Smith R, McKeown D, Raj J. Tests of human olfactory function: principal components analysis suggests that most measure a common source of variance. Percept Psychophys 1994;56:701-707.
33. Hummel T, Witt M, Reichmann H, Welge-Luessen A, Haehner A. Immunohistochemical, volumetric, and functional neuroimaging studies in patients with idiopathic Parkinson's disease. J Neurol Sci 2009;289:119-122.
34. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:436-446.
35. Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z. Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat 2007;211:117-124.
36. Silveira-Moriyama L, Holton JL, Kingsbury A, et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett 2009;453:77-80.
37. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
38. Assaf Y, Pasternak O. Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J Mol Neurosci 2008;34:51-61.
39. Boska MD, Hasan KM, Kibuule D, et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis 2007;26:590-596.
|
Language: | English.
|
Document Type: | Research Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0885-3185
|
DOI Number: | https://dx.doi.org/10.1002/mds.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|